BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 14609756)

  • 1. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
    Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
    Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.
    Driessens G; Gordower L; Nuttin L; Stordeur P; Blocklet D; Egrise D; Velu T; Bruyns C
    Cancer Immunol Immunother; 2008 Dec; 57(12):1745-56. PubMed ID: 18369621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
    Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
    Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
    Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
    Cheng WF; Lee CN; Chang MC; Su YN; Chen CA; Hsieh CY
    Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of lymphopoiesis as a function of the thymic microenvironment. Use of CD8+ cytotoxic T lymphocytes for cellular immunotherapy of human cancer.
    Bodey B
    In Vivo; 1994; 8(5):915-43. PubMed ID: 7727741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
    Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
    Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.
    Song S; Wang Y; Zhang Y; Wang F; He Y; Ren D; Guo Y; Sun S
    Cancer Lett; 2007 Oct; 256(1):90-100. PubMed ID: 17656012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.